Literature DB >> 1795010

Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

H O Klein1, G Golbach, P Voigt, C Coerper, C Bernhardt.   

Abstract

Three phase I/II trials were performed in patients with metastatic colorectal cancer using immunochemotherapy--a combination of recombinant interferon beta and gamma with low doses of cytostatic drugs. The third regimen, consisting of a cytostatic component containing 5-fluorouracil plus carboplatin plus mitomycin C besides the interferons, produced a high remission rate of 47%: 14/30 patients responded. The tolerability of this protocol was good and it could be administered on an out-patient basis.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1795010     DOI： 10.1007/BF01613230

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  42 in total

1.  Potentiation of release of interleukin-2 by bleomycin.

Authors:  T A Abdul Hamied; D Parker; J L Turk
Journal:  Immunopharmacology       Date:  1986-10

2.  Recombinant interferon-gamma lacks activity against metastatic colorectal cancer but increases serum levels of CA 19-9.

Authors:  M J O'Connell; R A Ritts; C G Moertel; A J Schutt; S A Sherwin
Journal:  Cancer       Date:  1989-05-15       Impact factor: 6.860

Review 3.  Towards tumor therapy with interferons, Part I. Interferons: production and properties.

Authors:  M Krim
Journal:  Blood       Date:  1980-05       Impact factor: 22.113

4.  Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer.

Authors:  P L Triozzi; P Kenney; D Young; J J Rinehart
Journal:  Cancer Treat Rep       Date:  1987-10

5.  Potentiation of the antiviral and anticellular activities of interferons by mixtures of HuIFN-gamma and HuIFN-alpha or HuIFN-beta.

Authors:  E Oleszak; W E Stewart
Journal:  J Interferon Res       Date:  1985

6.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

7.  Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer.

Authors:  J E Cantrell; R D Hart; R F Taylor; J H Harvey
Journal:  Cancer Treat Rep       Date:  1987-06

8.  Phase II trial of recombinant beta interferon in advanced colorectal cancer.

Authors:  P K Lillis; T D Brown; K Beougher; J Koeller; S G Marcus; D D Von Hoff
Journal:  Cancer Treat Rep       Date:  1987-10

9.  Sensitivity of human carcinoma cell lines to lysis by blood natural killer cells correlating with surface expression of carcinoembryonic antigen.

Authors:  D A Clark; P B McCulloch; S K Liao; P B Dent; A Fuks
Journal:  J Natl Cancer Inst       Date:  1984-03       Impact factor: 13.506

10.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307
View more
  1 in total

1.  Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.

Authors:  Ja Seon Kim; Young Min Park; Nha Young Kim; Han Kyeol Yun; Ki Jong Lee; Bo Hyun Kim; Sang Jong Park; Jae Woo Yeon; Guhung Jung
Journal:  Korean J Hepatol       Date:  2011-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.